<p>Allogene Therapeutics, Inc.（納斯達克代碼：ALLO - 獲取免費報告）週二上漲了 10.3%。該公司交易最高達到 2.29 美元，最後交易價格為 2.2950 美元。在交易期間，共交易了約 5,363,671 股，較平均每日交易量 5,955,742 股下降了 10%。該股票此前收盤價為 2.08 美元。</p>
<p>獲取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<ul>
<li>3 只空頭頭寸水平極高的股票</li>
</ul>
<p>多家研究公司最近對 ALLO 進行了評估。瑞銀集團在 1 月 7 日的研究報告中開始覆蓋 Allogene Therapeutics 的股票。他們給予該公司 “買入” 評級，並設定 8.00 美元的目標價。Citizens Jmp 在 1 月 9 日的報告中將 Allogene Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”，並設定 5.00 美元的目標價。花旗集團在 1 月 9 日的研究報告中將 Allogene Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”。最後，華爾街 Zen 在週日的研究報告中將 Allogene Therapeutics 的股票評級從 “賣出” 上調至 “持有”。十位股票研究分析師給予該股票 “買入” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 8.40 美元。</p>
<p><strong>查看我們最新的 ALLO 股票報告</strong></p>
<h2>Allogene Therapeutics 上漲 10.3%</h2>
<ul>
<li>你可能想買的 2 個醫療保健降級股票</li>
</ul>
<p>該公司的市值為 5.1576 億美元，市盈率為-2.34，貝塔值為 0.60。該公司的 50 日移動平均線為 1.62 美元，200 日移動平均線為 1.37 美元。</p>
<h2>內部人士買賣情況</h2>
<p>在其他 Allogene Therapeutics 的新聞中，執行副總裁 Zachary Roberts 在 2 月 2 日星期一以 1.77 美元的平均價格出售了 35,700 股該公司的股票，總價值為 63,189.00 美元。出售後，該執行副總裁直接持有 581,166 股公司股票，價值約為 1,028,663.82 美元。此交易代表其持股比例減少了 5.79%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 David D. Chang 在 2 月 2 日星期一以 1.80 美元的平均價格出售了 95,269 股該公司的股票，總交易額為 171,484.20 美元。交易後，首席執行官直接持有 5,185,862 股公司股票，價值約為 9,334,551.60 美元。此交易代表其持股比例減少了 1.80%。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了 215,855 股公司股票，價值 378,426 美元。公司內部人士持有公司股票的 13.20%。</p>
<h2>機構投資者對 Allogene Therapeutics 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Mercer Global Advisors Inc. ADV 在第四季度將其在 Allogene Therapeutics 的股份增加了 23.0%。Mercer Global Advisors Inc. ADV 現在擁有 29,512 股公司股票，價值 40,000 美元，此前在該期間內購買了 5,514 股。加拿大人壽保險公司在第三季度將其在 Allogene Therapeutics 的股份增加了 27.3%。加拿大人壽保險公司現在擁有 39,730 股公司股票，價值 50,000 美元，此前在上個季度購買了 8,519 股。Quadrature Capital Ltd 在第二季度將其在 Allogene Therapeutics 的股份增加了 29.6%。Quadrature Capital Ltd 現在擁有 44,050 股公司股票，價值 50,000 美元，此前在該期間內購買了 10,059 股。Brighton Jones LLC 在第三季度將其在 Allogene Therapeutics 的股份增加了 81.6%。Brighton Jones LLC 現在擁有 25,168 股公司股票，價值 31,000 美元，此前在上個季度購買了 11,311 股。最後，Zacks Investment Management 在第三季度將其在 Allogene Therapeutics 的股份增加了 2.7%。Zacks Investment Management 現在擁有 526,132 股公司股票，價值 652,000 美元，此前在該期間內購買了 13,831 股。機構投資者和對沖基金持有公司股票的 83.63%。</p>
<h2>Allogene Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Allogene Therapeutics 是一家臨牀階段的生物技術公司，專注於開發同種異體或 “現成” 的嵌合抗原受體 T 細胞（CAR T）療法，以治療一系列血液惡性腫瘤和實體腫瘤。該公司利用基因編輯技術生成普遍兼容的工程 T 細胞，旨在克服患者特定 CAR T 方法的侷限性，如生產延遲、產品質量不穩定和治療抵抗。</p>
<p>該公司的產品管線包括多個針對血癌關鍵抗原的同種異體 CAR T 候選藥物。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Allogene Therapeutics</li>
<li>當今最大科技趨勢背後的基礎</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
<li>沒有人談論的免費股票推薦</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Allogene Therapeutics 嗎？</h2>
<p>在考慮 Allogene Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Allogene Therapeutics 並不在名單上。</p>
<p>雖然 Allogene Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

ALLO

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Allogene Therapeutics (NASDAQ:ALLO) 的股價上漲了 10.3%，達到 2.2950 美元，成交量為 536 萬股。分析師給予的共識評級為 “適度買入”，平均目標價為 8.40 美元。最近的內部交易包括執行副總裁 Zachary Roberts 和首席執行官 David D. Chang 的出售。機構投資者持有該股票的 83.63%。Allogene 專注於開發用於血液惡性腫瘤和實體腫瘤的異基因 CAR T 療法，利用基因編輯技術</p>

<p>Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) rose 10.3% on Tuesday . The company traded as high as $2.29 and last traded at $2.2950. Approximately 5,363,671 shares were traded during trading, a decline of 10% from the average daily volume of 5,955,742 shares. The stock had previously closed at $2.08.</p>
<div class="lb-trans"><p>Allogene Therapeutics, Inc.（納斯達克代碼：ALLO - 獲取免費報告）週二上漲了 10.3%。該公司交易最高達到 2.29 美元，最後交易價格為 2.2950 美元。在交易期間，共交易了約 5,363,671 股，較平均每日交易量 5,955,742 股下降了 10%。該股票此前收盤價為 2.08 美元。</p>
</div><p>Get <strong>Allogene Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>3 Stocks With Sky-High Short Interest Levels</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只空頭頭寸水平極高的股票</li>
</ul>
</div><p>A number of research firms have recently weighed in on ALLO. UBS Group started coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $8.00 price target for the company. Citizens Jmp raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $5.00 price objective for the company in a report on Friday, January 9th. Citigroup raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of Allogene Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.40.</p>
<div class="lb-trans"><p>多家研究公司最近對 ALLO 進行了評估。瑞銀集團在 1 月 7 日的研究報告中開始覆蓋 Allogene Therapeutics 的股票。他們給予該公司 “買入” 評級，並設定 8.00 美元的目標價。Citizens Jmp 在 1 月 9 日的報告中將 Allogene Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”，並設定 5.00 美元的目標價。花旗集團在 1 月 9 日的研究報告中將 Allogene Therapeutics 的股票評級從 “市場表現” 上調至 “跑贏大盤”。最後，華爾街 Zen 在週日的研究報告中將 Allogene Therapeutics 的股票評級從 “賣出” 上調至 “持有”。十位股票研究分析師給予該股票 “買入” 評級，兩位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 8.40 美元。</p>
</div><p><strong>View Our Latest Stock Report on ALLO</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 ALLO 股票報告</strong></p>
</div><h2>Allogene Therapeutics Trading Up 10.3%</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 上漲 10.3%</h2>
</div><ul>
<li>2 Downgrades in Healthcare You Might Want to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能想買的 2 個醫療保健降級股票</li>
</ul>
</div><p>The firm has a market cap of $515.76 million, a P/E ratio of -2.34 and a beta of 0.60. The business's 50-day moving average is $1.62 and its two-hundred day moving average is $1.37.</p>
<div class="lb-trans"><p>該公司的市值為 5.1576 億美元，市盈率為-2.34，貝塔值為 0.60。該公司的 50 日移動平均線為 1.62 美元，200 日移動平均線為 1.37 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of the firm's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president directly owned 581,166 shares in the company, valued at approximately $1,028,663.82. This trade represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David D. Chang sold 95,269 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares of the company's stock, valued at approximately $9,334,551.60. This trade represents a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 215,855 shares of company stock worth $378,426. Company insiders own 13.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Allogene Therapeutics 的新聞中，執行副總裁 Zachary Roberts 在 2 月 2 日星期一以 1.77 美元的平均價格出售了 35,700 股該公司的股票，總價值為 63,189.00 美元。出售後，該執行副總裁直接持有 581,166 股公司股票，價值約為 1,028,663.82 美元。此交易代表其持股比例減少了 5.79%。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 David D. Chang 在 2 月 2 日星期一以 1.80 美元的平均價格出售了 95,269 股該公司的股票，總交易額為 171,484.20 美元。交易後，首席執行官直接持有 5,185,862 股公司股票，價值約為 9,334,551.60 美元。此交易代表其持股比例減少了 1.80%。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了 215,855 股公司股票，價值 378,426 美元。公司內部人士持有公司股票的 13.20%。</p>
</div><h2>Institutional Investors Weigh In On Allogene Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Allogene Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV boosted its position in shares of Allogene Therapeutics by 23.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company's stock valued at $40,000 after purchasing an additional 5,514 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in Allogene Therapeutics by 27.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company's stock valued at $50,000 after buying an additional 8,519 shares in the last quarter. Quadrature Capital Ltd boosted its holdings in shares of Allogene Therapeutics by 29.6% in the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company's stock worth $50,000 after buying an additional 10,059 shares during the period. Brighton Jones LLC increased its position in shares of Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock worth $31,000 after acquiring an additional 11,311 shares in the last quarter. Finally, Zacks Investment Management raised its holdings in shares of Allogene Therapeutics by 2.7% during the third quarter. Zacks Investment Management now owns 526,132 shares of the company's stock valued at $652,000 after acquiring an additional 13,831 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Mercer Global Advisors Inc. ADV 在第四季度將其在 Allogene Therapeutics 的股份增加了 23.0%。Mercer Global Advisors Inc. ADV 現在擁有 29,512 股公司股票，價值 40,000 美元，此前在該期間內購買了 5,514 股。加拿大人壽保險公司在第三季度將其在 Allogene Therapeutics 的股份增加了 27.3%。加拿大人壽保險公司現在擁有 39,730 股公司股票，價值 50,000 美元，此前在上個季度購買了 8,519 股。Quadrature Capital Ltd 在第二季度將其在 Allogene Therapeutics 的股份增加了 29.6%。Quadrature Capital Ltd 現在擁有 44,050 股公司股票，價值 50,000 美元，此前在該期間內購買了 10,059 股。Brighton Jones LLC 在第三季度將其在 Allogene Therapeutics 的股份增加了 81.6%。Brighton Jones LLC 現在擁有 25,168 股公司股票，價值 31,000 美元，此前在上個季度購買了 11,311 股。最後，Zacks Investment Management 在第三季度將其在 Allogene Therapeutics 的股份增加了 2.7%。Zacks Investment Management 現在擁有 526,132 股公司股票，價值 652,000 美元，此前在該期間內購買了 13,831 股。機構投資者和對沖基金持有公司股票的 83.63%。</p>
</div><h2>Allogene Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.</p>
<div class="lb-trans"><p>Allogene Therapeutics 是一家臨牀階段的生物技術公司，專注於開發同種異體或 “現成” 的嵌合抗原受體 T 細胞（CAR T）療法，以治療一系列血液惡性腫瘤和實體腫瘤。該公司利用基因編輯技術生成普遍兼容的工程 T 細胞，旨在克服患者特定 CAR T 方法的侷限性，如生產延遲、產品質量不穩定和治療抵抗。</p>
</div><p>The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個針對血癌關鍵抗原的同種異體 CAR T 候選藥物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Allogene Therapeutics</li>
<li>The Foundation Behind Today's Biggest Tech Trends</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
<li>The free stock picks nobody’s talking about</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Allogene Therapeutics</li>
<li>當今最大科技趨勢背後的基礎</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
<li>沒有人談論的免費股票推薦</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Allogene Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Allogene Therapeutics 嗎？</h2>
</div><p>Before you consider Allogene Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Allogene Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Allogene Therapeutics 並不在名單上。</p>
</div><p>While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Allogene Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%  - Should You Buy?

Market Beat

Allogene Therapeutics

Invesco Nasdaq Biotechnology ETF

Allogene Therapeutics (NASDAQ:ALLO) 的股價上漲了 10.3% - 你是否應該購買？